Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma
Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cell...
Gespeichert in:
Veröffentlicht in: | Journal of neuro-oncology 2004-02, Vol.66 (3), p.351-360 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 360 |
---|---|
container_issue | 3 |
container_start_page | 351 |
container_title | Journal of neuro-oncology |
container_volume | 66 |
creator | GIESE, Alf KUCINSKI, Thomas KNOPP, Ulrich GOLDBRUNNER, Roland HAMEL, Wolfgang MEBDORN, H. M TONN, Jörg C HILT, Dana WESTPHAL, Manfred |
description | Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cells in adjacent brain possibly leading to a local control of the tumor and increased survival.
We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL Wafers or placebo wafers following resection of glioblastomas.
Of 24 patients 11 received carmustine wafers and 13 placebo. The age distribution and Karnowsky performance scores of the two populations were not different. However, the median survival (14.7 versus 9.5 months; P = 0.007) and the time to neurological deterioration (12.9 +/- 4.85 vs. 9.4 +/- 2.73 months; P = 0.035) was significantly longer in the treatment group versus the placebo treated control. Preoperative and follow up MRI studies were evaluated in a blinded fashion. Out of 24 patients that entered the analysis 11 showed clearance of all contrast enhancement following resection of glioblastomas. Seventeen tumors progressed locally and 7 showed different patterns of distant failure. Within the carmustine treated group 8 patients showed a local treatment failure with recurrent tumors immediately adjacent to the resection cavity or progression form a residual tumor. Three patients showed a multifocal distant and local pattern of failure after complete or subtotal removal. In no case the local chemotherapy resulted in a distant recurrence only. However, the time to radiographic progression was 165.1 +/- 80.75 days for the GLIADEL Wafer group and 101.9 +/- 43.06 days for the placebo group (P = 0.023).
In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. Local chemotherapy with carmustine containing wafer implants did not result in an altered pattern of recurrence and did not promote multifocal patterns of recurrence. |
doi_str_mv | 10.1023/B:NEON.0000014539.90077.db |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_219579032</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>815865181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-ad38c3e034acff8f352dfbc5cfc5b2c4b2adc269d01c7ee7dcc5547fa36e67283</originalsourceid><addsrcrecordid>eNpNkEtrGzEURkVpady0f6GIQKFdjKPHaGRlV5v0AcHJooHuhJ62gmY0lTSEbPLbM04M6d3cuzjf_eAAcIbREiNCz9cX28vr7RIdBreMiqVAiPOl1W_AAjNOG045fQsWCHe8YaL9ewI-lHI34y2n-D04wQxh1nWrBXi8UbW6PMDkYXZmytkNxkGfYkz3YdjBmIyK0Oxdn-reZTU-wPtQ91CHZN0uK6t0dNCo3E-lhsHBr-vN9vYbDP0Y1VALDAMcVQ3ucD8ndzEkHVWpqVcfwTuvYnGfjvsU3P64_LP51Vxd__y9-X7VmJaI2ihLV4Y6RFtlvF95yoj12jDjDdPEtJooa0gnLMKGO8etMYy13CvauY6TFT0FZy9_x5z-Ta5UeZemPMyVkmDBuECUzNDFC2RyKiU7L8ccepUfJEbyYF6u5cG8fDUvn81Lq-fw52PDpHtnX6NH1TPw5QioMiv1WQ0mlP-4VlAqMH0CSneRBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219579032</pqid></control><display><type>article</type><title>Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>GIESE, Alf ; KUCINSKI, Thomas ; KNOPP, Ulrich ; GOLDBRUNNER, Roland ; HAMEL, Wolfgang ; MEBDORN, H. M ; TONN, Jörg C ; HILT, Dana ; WESTPHAL, Manfred</creator><creatorcontrib>GIESE, Alf ; KUCINSKI, Thomas ; KNOPP, Ulrich ; GOLDBRUNNER, Roland ; HAMEL, Wolfgang ; MEBDORN, H. M ; TONN, Jörg C ; HILT, Dana ; WESTPHAL, Manfred</creatorcontrib><description>Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cells in adjacent brain possibly leading to a local control of the tumor and increased survival.
We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL Wafers or placebo wafers following resection of glioblastomas.
Of 24 patients 11 received carmustine wafers and 13 placebo. The age distribution and Karnowsky performance scores of the two populations were not different. However, the median survival (14.7 versus 9.5 months; P = 0.007) and the time to neurological deterioration (12.9 +/- 4.85 vs. 9.4 +/- 2.73 months; P = 0.035) was significantly longer in the treatment group versus the placebo treated control. Preoperative and follow up MRI studies were evaluated in a blinded fashion. Out of 24 patients that entered the analysis 11 showed clearance of all contrast enhancement following resection of glioblastomas. Seventeen tumors progressed locally and 7 showed different patterns of distant failure. Within the carmustine treated group 8 patients showed a local treatment failure with recurrent tumors immediately adjacent to the resection cavity or progression form a residual tumor. Three patients showed a multifocal distant and local pattern of failure after complete or subtotal removal. In no case the local chemotherapy resulted in a distant recurrence only. However, the time to radiographic progression was 165.1 +/- 80.75 days for the GLIADEL Wafer group and 101.9 +/- 43.06 days for the placebo group (P = 0.023).
In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. Local chemotherapy with carmustine containing wafer implants did not result in an altered pattern of recurrence and did not promote multifocal patterns of recurrence.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1023/B:NEON.0000014539.90077.db</identifier><identifier>PMID: 15015668</identifier><identifier>CODEN: JNODD2</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Absorbable Implants ; Adolescent ; Adult ; Age Distribution ; Aged ; Antineoplastic Agents, Alkylating - therapeutic use ; Biological and medical sciences ; Brain Neoplasms - drug therapy ; Brain Neoplasms - pathology ; Carmustine - therapeutic use ; Drug Implants ; Glioblastoma - drug therapy ; Glioblastoma - pathology ; Humans ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local - pathology ; Neurology ; Prospective Studies ; Randomized Controlled Trials as Topic ; Survival Rate</subject><ispartof>Journal of neuro-oncology, 2004-02, Vol.66 (3), p.351-360</ispartof><rights>2004 INIST-CNRS</rights><rights>Kluwer Academic Publishers 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-ad38c3e034acff8f352dfbc5cfc5b2c4b2adc269d01c7ee7dcc5547fa36e67283</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15493391$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15015668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GIESE, Alf</creatorcontrib><creatorcontrib>KUCINSKI, Thomas</creatorcontrib><creatorcontrib>KNOPP, Ulrich</creatorcontrib><creatorcontrib>GOLDBRUNNER, Roland</creatorcontrib><creatorcontrib>HAMEL, Wolfgang</creatorcontrib><creatorcontrib>MEBDORN, H. M</creatorcontrib><creatorcontrib>TONN, Jörg C</creatorcontrib><creatorcontrib>HILT, Dana</creatorcontrib><creatorcontrib>WESTPHAL, Manfred</creatorcontrib><title>Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><description>Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cells in adjacent brain possibly leading to a local control of the tumor and increased survival.
We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL Wafers or placebo wafers following resection of glioblastomas.
Of 24 patients 11 received carmustine wafers and 13 placebo. The age distribution and Karnowsky performance scores of the two populations were not different. However, the median survival (14.7 versus 9.5 months; P = 0.007) and the time to neurological deterioration (12.9 +/- 4.85 vs. 9.4 +/- 2.73 months; P = 0.035) was significantly longer in the treatment group versus the placebo treated control. Preoperative and follow up MRI studies were evaluated in a blinded fashion. Out of 24 patients that entered the analysis 11 showed clearance of all contrast enhancement following resection of glioblastomas. Seventeen tumors progressed locally and 7 showed different patterns of distant failure. Within the carmustine treated group 8 patients showed a local treatment failure with recurrent tumors immediately adjacent to the resection cavity or progression form a residual tumor. Three patients showed a multifocal distant and local pattern of failure after complete or subtotal removal. In no case the local chemotherapy resulted in a distant recurrence only. However, the time to radiographic progression was 165.1 +/- 80.75 days for the GLIADEL Wafer group and 101.9 +/- 43.06 days for the placebo group (P = 0.023).
In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. Local chemotherapy with carmustine containing wafer implants did not result in an altered pattern of recurrence and did not promote multifocal patterns of recurrence.</description><subject>Absorbable Implants</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - pathology</subject><subject>Carmustine - therapeutic use</subject><subject>Drug Implants</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - pathology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neurology</subject><subject>Prospective Studies</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Survival Rate</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpNkEtrGzEURkVpady0f6GIQKFdjKPHaGRlV5v0AcHJooHuhJ62gmY0lTSEbPLbM04M6d3cuzjf_eAAcIbREiNCz9cX28vr7RIdBreMiqVAiPOl1W_AAjNOG045fQsWCHe8YaL9ewI-lHI34y2n-D04wQxh1nWrBXi8UbW6PMDkYXZmytkNxkGfYkz3YdjBmIyK0Oxdn-reZTU-wPtQ91CHZN0uK6t0dNCo3E-lhsHBr-vN9vYbDP0Y1VALDAMcVQ3ucD8ndzEkHVWpqVcfwTuvYnGfjvsU3P64_LP51Vxd__y9-X7VmJaI2ihLV4Y6RFtlvF95yoj12jDjDdPEtJooa0gnLMKGO8etMYy13CvauY6TFT0FZy9_x5z-Ta5UeZemPMyVkmDBuECUzNDFC2RyKiU7L8ccepUfJEbyYF6u5cG8fDUvn81Lq-fw52PDpHtnX6NH1TPw5QioMiv1WQ0mlP-4VlAqMH0CSneRBg</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>GIESE, Alf</creator><creator>KUCINSKI, Thomas</creator><creator>KNOPP, Ulrich</creator><creator>GOLDBRUNNER, Roland</creator><creator>HAMEL, Wolfgang</creator><creator>MEBDORN, H. M</creator><creator>TONN, Jörg C</creator><creator>HILT, Dana</creator><creator>WESTPHAL, Manfred</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20040201</creationdate><title>Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma</title><author>GIESE, Alf ; KUCINSKI, Thomas ; KNOPP, Ulrich ; GOLDBRUNNER, Roland ; HAMEL, Wolfgang ; MEBDORN, H. M ; TONN, Jörg C ; HILT, Dana ; WESTPHAL, Manfred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-ad38c3e034acff8f352dfbc5cfc5b2c4b2adc269d01c7ee7dcc5547fa36e67283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Absorbable Implants</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - pathology</topic><topic>Carmustine - therapeutic use</topic><topic>Drug Implants</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - pathology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neurology</topic><topic>Prospective Studies</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GIESE, Alf</creatorcontrib><creatorcontrib>KUCINSKI, Thomas</creatorcontrib><creatorcontrib>KNOPP, Ulrich</creatorcontrib><creatorcontrib>GOLDBRUNNER, Roland</creatorcontrib><creatorcontrib>HAMEL, Wolfgang</creatorcontrib><creatorcontrib>MEBDORN, H. M</creatorcontrib><creatorcontrib>TONN, Jörg C</creatorcontrib><creatorcontrib>HILT, Dana</creatorcontrib><creatorcontrib>WESTPHAL, Manfred</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GIESE, Alf</au><au>KUCINSKI, Thomas</au><au>KNOPP, Ulrich</au><au>GOLDBRUNNER, Roland</au><au>HAMEL, Wolfgang</au><au>MEBDORN, H. M</au><au>TONN, Jörg C</au><au>HILT, Dana</au><au>WESTPHAL, Manfred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma</atitle><jtitle>Journal of neuro-oncology</jtitle><addtitle>J Neurooncol</addtitle><date>2004-02-01</date><risdate>2004</risdate><volume>66</volume><issue>3</issue><spage>351</spage><epage>360</epage><pages>351-360</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><coden>JNODD2</coden><abstract>Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. A local chemotherapy applied directly to the resection cavity may act directly on residual tumor cells in adjacent brain possibly leading to a local control of the tumor and increased survival.
We have analyzed the pattern of recurrence using serial MRI studies of 24 patients treated with GLIADEL Wafers or placebo wafers following resection of glioblastomas.
Of 24 patients 11 received carmustine wafers and 13 placebo. The age distribution and Karnowsky performance scores of the two populations were not different. However, the median survival (14.7 versus 9.5 months; P = 0.007) and the time to neurological deterioration (12.9 +/- 4.85 vs. 9.4 +/- 2.73 months; P = 0.035) was significantly longer in the treatment group versus the placebo treated control. Preoperative and follow up MRI studies were evaluated in a blinded fashion. Out of 24 patients that entered the analysis 11 showed clearance of all contrast enhancement following resection of glioblastomas. Seventeen tumors progressed locally and 7 showed different patterns of distant failure. Within the carmustine treated group 8 patients showed a local treatment failure with recurrent tumors immediately adjacent to the resection cavity or progression form a residual tumor. Three patients showed a multifocal distant and local pattern of failure after complete or subtotal removal. In no case the local chemotherapy resulted in a distant recurrence only. However, the time to radiographic progression was 165.1 +/- 80.75 days for the GLIADEL Wafer group and 101.9 +/- 43.06 days for the placebo group (P = 0.023).
In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time. Local chemotherapy with carmustine containing wafer implants did not result in an altered pattern of recurrence and did not promote multifocal patterns of recurrence.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>15015668</pmid><doi>10.1023/B:NEON.0000014539.90077.db</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-594X |
ispartof | Journal of neuro-oncology, 2004-02, Vol.66 (3), p.351-360 |
issn | 0167-594X 1573-7373 |
language | eng |
recordid | cdi_proquest_journals_219579032 |
source | MEDLINE; SpringerNature Journals |
subjects | Absorbable Implants Adolescent Adult Age Distribution Aged Antineoplastic Agents, Alkylating - therapeutic use Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - pathology Carmustine - therapeutic use Drug Implants Glioblastoma - drug therapy Glioblastoma - pathology Humans Medical sciences Middle Aged Neoplasm Recurrence, Local - pathology Neurology Prospective Studies Randomized Controlled Trials as Topic Survival Rate |
title | Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T00%3A33%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pattern%20of%20recurrence%20following%20local%20chemotherapy%20with%20biodegradable%20carmustine%20(BCNU)%20implants%20in%20patients%20with%20glioblastoma&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=GIESE,%20Alf&rft.date=2004-02-01&rft.volume=66&rft.issue=3&rft.spage=351&rft.epage=360&rft.pages=351-360&rft.issn=0167-594X&rft.eissn=1573-7373&rft.coden=JNODD2&rft_id=info:doi/10.1023/B:NEON.0000014539.90077.db&rft_dat=%3Cproquest_cross%3E815865181%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219579032&rft_id=info:pmid/15015668&rfr_iscdi=true |